Biomarkers for radiation treatment

Patent metadata

Field	Value
Publication number	US-9938583-B2
Application number	US-201414777209-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-β expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-β inhibitors with ionizing radiation to treat cancer patients.

First claim

What is claimed is:

1. A method for treating a tumor in a subject, the method comprising:
i) contacting a tumor sample from the subject with antibodies that bind to biomarkers CD44 and CD68;
ii) contacting a normal tissue sample with antibodies that bind to the biomarkers CD44 and CD68;
iii) detecting increased expression of CD44 and CD68 in the tumor sample as compared to the normal tissue sample, and
iv) administering an effective dose of ionizing radiation to the tumor and a TGF-beta inhibitor to the subject, thereby treating the tumor, wherein the TGF-beta inhibitor is an antibody or a small molecule.

2. The method of claim 1 , wherein the dose of ionizing radiation is administered to the tumor by hypofractionation.

3. The method of claim 1 , wherein the dose of ionizing radiation is administered to the tumor by hyperfractionation.

4. The method of claim 1 , wherein the treatment further comprises administering an anti-cancer agent to the subject, wherein the anti-cancer agent is a chemotherapeutic agent, radiosensitizer, or immune modulator.

5. The method of claim 1 , wherein the biomarker is a protein.

6. The method of claim 1 , wherein the biomarker is detected by immunohistochemistry, ELISA, Western analysis, or digital pathology.

7. The method of claim 1 , wherein the normal tissue sample comprises non-tumor cells from the same tissue type as the tumor.

8. The method of claim 1 , further comprising determining the expression level of at least one additional biomarker from the tumor sample.

Assignees

• Varian Med Sys Inc

Inventors

• Parry Renate

Classifications

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title

• A61N5/1064

  for adjusting radiation treatment in response to monitoring · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• A61N2005/1098

  Enhancing the effect of the particle by an injected agent or implanted device · CPC title

• C12Q2600/158

  Expression markers · CPC title